title: Post-approval fate of pharmaceutical companies.
abstract: For a fortunate subset of pharmaceutical companies, a regulatory approval is the culmination of massive investment in time, work and money. What happens next? Some companies proceed to build a pipeline and obtain additional approvals. Others do not. In this present report, post-approval fate is evaluated and it was found that most companies are ultimately acquired. A subset achieved a second approval six-to-eight years after the first approval, whereas a shrinking subset, designated as 'singlets', remains active in drug discovery with only a single approval. The likelihood that a company will remain a singlet or be acquired relates to therapeutic indication, with oncology associated with increased acquisition potential and infectious-disease-based companies being less commonly acquired.
authors.affiliation: Washington University in St Louis, 4240 Duncan Street, Suite 110, St Louis, MO 63110, USA. Electronic address: michael.kinch@wustl.edu.
authors.forename: Michael S
authors.initials: MS
authors.lastname: Kinch
mesh_terms: D017277:Drug Approval / Q000706:statistics & numerical data*; D004345:Drug Industry / Q000706:statistics & numerical data / Q000639:trends*; D015507:Drugs, Investigational
chemical_list: D015507:Drugs, Investigational